Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Harnessing advanced data analysis for early detection, prevention and better outcomes
Final decision from the European Commission is anticipated within the coming months
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Subscribe To Our Newsletter & Stay Updated
